| abstract |
The present invention provides a molecule such as an antibody that selectively binds to glycated BTLA (B- and T-lymphocyte weakening factor) relative to unaltered BTLA. Methods of making and using such molecules, including methods of treating or diagnosing cancer, are also provided. In some embodiments, the anti-glycated BTLA antibodies provided herein can bind immunogically to the glycated wild-type BTLA (WT). In some embodiments, the anti-glycated BTLA antibody provided herein can bind to one or more BTLA dual mutants that only have a single glycosylation site in BTLA N75, N94 or N110. In some embodiments, the anti-glycated BTLA antibody provided herein exhibits only background binding, if any, for a BTLA triple mutant that does not have a glycosylation site in either N75, N94 or N110 of BTLA. |